Fiber Supplements for IBS (Irritable Bowel Syndrome)

A 2014 meta-analysis of 14 trials (906 adults) found soluble fiber lowered the risk of staying symptomatic (RR 0.83, 95% CI 0.73-0.94; number needed to treat 7), while wheat bran did not (RR 0.90, 95% CI 0.79-1.03). A 2026 meta-analysis of 30 trials (1,904 adults) found 52% responded to fiber versus 44% on control (RR 1.21), with a clearer benefit for psyllium (RR 1.53, 95% CI 1.06-2.19).

The gain is real but modest, and not every measure moves. In that 2026 analysis, overall symptom scores did not change significantly (SMD -0.25, 95% CI -0.67 to 0.17), and a 1981 trial found psyllium no better than placebo. Treat soluble fiber as a low-risk first step for IBS, not a fix, and skip wheat bran.

Psyllium is a soluble, gel-forming fiber that resists fermentation in the colon. The ACG guideline notes that fibers with laxative effects tend to increase stool water content and resist colonic fermentation, while fibers that ferment lose their water-holding capacity and produce gas that can aggravate bloating and flatulence. That is the working rationale for choosing soluble, poorly fermentable fiber.

In the 1987 ispaghula trial, transit time fell significantly (P = 0.001) and constipation improved (P = 0.026) compared with placebo, which fits a bulking effect in people whose IBS comes with slow stools.

Better stool bulk does not explain pain. The same 1987 trial found abdominal pain and bloating improved in both groups with no significant difference from placebo, and the 2004 review found no evidence that fiber relieved abdominal pain. A 2015 meta-analysis did report lower pain scores on soluble fiber (mean difference -1.84), so the pain evidence is mixed.

Fermentable fibers behave differently. In 19 people with IBS, 20 g of inulin raised colonic gas on MRI, and taking 20 g of psyllium with it brought gas back to placebo levels (P = 0.02) without stopping fermentation in the lab. That is a mechanistic signal from a small crossover study, not proof that psyllium makes prebiotics comfortable to take.

The largest primary-care trial gave 10 g of psyllium a day for 12 weeks. The British Society of Gastroenterology (BSG) 2021 guideline advises starting soluble fiber at 3-4 g a day and building up gradually to avoid bloating, and rates that advice a strong recommendation on moderate-quality evidence. The abstracts of the other trials reviewed here do not report their doses, so there is no established ceiling to quote.

Take each dose with plenty of fluid. US labeling rules for bulk-forming fiber warn to take it with at least 8 ounces (a full glass) of water or other fluid because taking it without enough liquid may cause choking.

Four independent meta-analyses agree on the direction. Moayyedi (2014): 14 trials, 906 adults, RR of remaining symptomatic 0.86 overall and 0.83 for soluble fiber. Ford (2008): 12 trials, 591 adults, RR 0.87 overall (95% CI 0.76-1.00), limited to ispaghula (RR 0.78). Nagarajan (2015): global symptoms improved with fiber (RR 1.27) and with soluble fiber (RR 1.49). Bijkerk (2004): soluble fiber RR 1.55 and IBS with constipation RR 1.56.

The newest, Staudacher (2026), pooled 30 trials in 1,904 adults. Response was 52% on fiber vs 44% on control (RR 1.21, 95% CI 1.03-1.41; P = 0.02) and psyllium specifically gave a 53% higher relative response (RR 1.53). For overall symptom scores, 9 trials (497 adults) found no significant effect, with high heterogeneity (I2 = 78%).

Bijkerk (2009) randomised 275 adults in general practice to 10 g psyllium, 10 g bran or rice-flour placebo for 12 weeks. Psyllium responders were 57% vs 35% in month 1 (RR 1.60) and 59% vs 41% in month 2 (RR 1.44), and severity fell 90 points vs 49 on placebo (P = 0.03). Quality of life did not differ, and only 64% of the psyllium group finished.

Prior and Whorwell (1987) found 82% vs 53% judged treatment satisfactory on ispaghula (P < 0.02) in 80 patients. But Longstreth (1981), in 77 patients with painful IBS, found psyllium and placebo improved equally and concluded a major placebo effect was probably responsible. Honest reading: the older trials conflict, and the better-designed recent ones lean positive.

The 2026 meta-analysis could not analyse most outcomes by IBS subtype, so whether fiber suits IBS with diarrhea is not answered here. The 2020 network meta-analysis (51 trials, 4,644 patients) found only 13 trials at low risk of bias and no significant differences between active treatments for global symptoms, though peppermint oil ranked first (RR 0.63). Treatment lengths of 4-12 weeks mean long-term benefit is unknown.

Fiber looks well tolerated. The ACG guideline reports adverse events in 36% of 355 people on fiber and 25.1% of 251 on placebo, a difference that was not significant (RR 1.06, 95% CI 0.92-1.22). The risk is bloating and gas, which is why the BSG guideline says to build up gradually.

The practical hazard is fluid: bulk-forming fiber labels carry a choking warning if taken without a full glass of liquid. In the 2009 trial, the group on bran, not psyllium, dropped out early mainly because symptoms worsened.

Fiber has few documented interactions. The one studied here is levothyroxine, where the delay was small.